Tak Paul Peter 4

What Happened

• Tak Paul Peter, CEO of Candel Therapeutics, was granted a derivative award on 2026-01-26 covering 629,000 shares. The Form 4 reports the acquisition price as $0.00 per share; the award is a time‑based option that vests monthly over four years (see footnote). This is a compensation award, not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-01-26; Form 4 filed: 2026-01-28 (appears timely).
• Transaction type/code: A (Award/Grant of a derivative security).
• Amount: 629,000 shares (derivative securities); price reported: $0.00.
• Vesting: 48 equal monthly installments beginning after January 26, 2026 (footnote F1); vesting contingent on continued service.
• Shares owned after transaction: not disclosed in the excerpt provided.
• No 10b5‑1 plan, tax withholding, or sale reported in this filing.

Context

• This is a typical executive compensation grant meant to align management incentives with shareholder value; it does not represent a cash purchase or sale by the CEO. Because the award vests over time, it signals future potential dilution as shares/options vest, but it is primarily a retention/compensation mechanism rather than an immediate market action.